CN104531730B - Clostridium perfringens alpha toxin Humanized single chain antibody 8B - Google Patents

Clostridium perfringens alpha toxin Humanized single chain antibody 8B Download PDF

Info

Publication number
CN104531730B
CN104531730B CN201410771046.3A CN201410771046A CN104531730B CN 104531730 B CN104531730 B CN 104531730B CN 201410771046 A CN201410771046 A CN 201410771046A CN 104531730 B CN104531730 B CN 104531730B
Authority
CN
China
Prior art keywords
antibody
ser
gly
alpha toxin
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410771046.3A
Other languages
Chinese (zh)
Other versions
CN104531730A (en
Inventor
张国利
于佳
朱进
田园
刘雨玲
陈萍
岳玉环
吴广谋
史飞
徐艳玲
赵鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Military Veterinary Academy of Military Medical Sciences PLA
Original Assignee
Institute of Military Veterinary Academy of Military Medical Sciences PLA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Military Veterinary Academy of Military Medical Sciences PLA filed Critical Institute of Military Veterinary Academy of Military Medical Sciences PLA
Priority to CN201410771046.3A priority Critical patent/CN104531730B/en
Publication of CN104531730A publication Critical patent/CN104531730A/en
Application granted granted Critical
Publication of CN104531730B publication Critical patent/CN104531730B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention discloses clostridium perfringens alpha toxin Humanized single chain antibody 8B, it is screened from phage antibody library Source bioscience, it is the anti-clostridium perfringens alpha toxin antibody in full people source, both the therapeutic effect to neutralize a toxin may be implemented, a variety of side effects of heterogenetic antibody are overcome simultaneously, it eliminates heterogenetic antibody and carries out humanization modified tedious steps and high cost, since single-chain antibody molecules amount is small, internal penetration capacity is strong, it is rapid to reach damaged tissues and the effect of cells play antitoxin, therefore reach economic and efficient dual purpose.Alpha toxin with C.perfringens other types toxin there is certain homology, the antibody drug to be possible to having inhibition and therapeutic effect to other kinds of toxin, also can be used as detection reagent detection clostridium perfringens alpha toxin.

Description

Clostridium perfringens alpha toxin Humanized single chain antibody 8B
Technical field
The invention belongs to bioengineering and disease prevention and cure fields, more particularly to clostridium perfringens alpha toxin humanization list The application of chain antibody 8B and its diagnostic and therapeutic method of being poisoned in clostridium perfringens alpha toxin.
Background technology
C.perfringens(Clostridium perfringens)Also known as clostridieum welchii (C.welchii) is gram Positive bacteria, shape are the coarse rod-shaped of both ends blunt circle, and obligate anaerobic has pod membrane atrichia, are to cause people's food poisoning, gas bad The main pathogenic fungi of subcutaneous ulcer, antibiotic-associated diarrhea and the diseases such as the enterotoxemia of animal and dysentery.C.perfringens one As under the conditions of be hardly formed gemma, gemma is advantageously formed in sugar-free culture-medium, most clostridium perfringens strains can be formed The G+C mol% of pod membrane, the DNA of bacteria are 24-27.The energy normal growth on minimal medium, suitable growth temperature is in 37- 47 DEG C, show round, raised, smooth, translucent, neat in edge, nothing migrates growth phenomenon.C.perfringens is that one kind is detested Oxygen bacterium is separately cultured and special equipment and reagent, common laboratory is needed to be difficult to carry out the research of the bacterium, therefore state for a long time The interior effect to anaerobic bacteria and its in food poisoning also lacks understanding, although external have the report poisoned by food caused by anaerobic bacteria Road, but it is domestic it is less appear in the newspapers, the bacterium as a kind of conditioned pathogen, be widely present in nature water source, soil and people and Among animal intestinal tract.When eating every gram of bacteria containing amount up to 105When the above contaminated food products, you can cause to poison by food, clinical manifestation For nausea and vomiting, cramp, multiple diarrhea, phenomena such as fever.Up to the present, it has been found that the bacterium exotoxin have 16 kinds (α, β, γ, δ, ε, η, θ, ι, κ, λ, μ and ν etc.), but only several toxin, i.e. α (CPA), β (CPB), ε (ETX), ι (ITX) poison Element and C.perfringens lysin O(PFO), enterotoxin(CPE), β 2 (CPB2) toxin be considered as the bacterium principal causative Toxin.Four kinds of lethal toxins are generated according to C.perfringens(α, β, ε, ι toxin)Ability, be classified as five kinds of serum classes Type, i.e. A, B, C, D and E type, wherein A types mainly cause the food poisoning and antibiotic-associated diarrhea of the mankind, can also cause The emphysematous gangrene of animal can also cause the enterotoxemia of ox, lamb, reinder, piglet and rabbit;Type B bacterium mainly causes lamb Dysentery can also cause the enterotoxemia such as dog, ox and sheep or necrotic enteritis;C-type bacterium is mainly the pathogen of struck, It can cause the enterotoxemia, necrotic enteritis and the necrotic enteritis of people of lamb, ox, piglet and sheep;D type bacterium cause sheep, The enterotoxemia of ox, piglet and squirrel;E types bacterium can cause calf, lamb enterotoxemia, but seldom occur, wherein various equal Alpha toxin can be generated, it is seen that alpha toxin is the primary toxins and virulence factor of C.perfringens.
Clostridium perfringens alpha toxin(Clostridium perfringens alpha-toxin, CPA)It is to cause people and animals Gangrene after trauma and human foods poisoning major virulent factor.Alpha toxin is a kind of dependent on the multi-functional of zinc ion Metalloenzyme has membrane phospholipid C (PLC) and sphingomyelinase(SMase)Two kinds of enzymatic activitys, can simultaneously hydrolyzed cellular film phosphatidyl Choline and sphingomyelins destroy the integrality of cell membrane, lead to cell cracking, have cytotoxicity, hemolytic activity, cutaneous necrosis Property, platelet aggregation and increase the characteristics such as vascular permeability.Clostridium perfringens alpha toxin is a kind of bacteriotoxin for defying oxygen, Phosphatidyl choline and insoluble dialycerides can be formed with hydrolyzed lecithin, make red blood cell that haemolysis occur and decompose lecithin. Aerosol form release can be made as biological weapons by purifying the clostridium perfringens alpha toxin of concentration, can also be discharged in water In food, which can cause the severe reaction of people's multisystem multiple organ, such as lack appetite, nausea and vomiting, stomach convulsion Contraction pain, sanguinopurulent diarrhea;Have difficulty in breathing, cough of panting, oral cavity and throat pain, blood-stained sputum;Skin scorch pain, redness, itch, Fash or bubble, it is more serious to cause death.Alpha toxin is first and is found existing enzymatic activity again and has the thin of toxin characteristic Mycoprotein, have hot-cold hemolysis effect, i.e., alpha toxin 37 DEG C with red blood cell act on when, red blood cell does not crack, only when Red blood cell change can just crack, this hot-cold hemolysis effect when being cooled to 4 DEG C, find mouse red blood cell, family's rabbit erythrocyte, On sheep red blood cell (SRBC) and Ho RBC.Alpha toxin is sensitive to pancreatin, and 2.5% pancreatin acts on 1 h at 37 DEG C with alpha toxin, you can makes Its complete deactivation.In addition, when alpha toxin is heated to 60 DEG C -70 DEG C, so that it may so that it is inactivated, when being further heated to 100 DEG C When, what is had can be with recovered part activity.Alpha toxin structural gene size is 1194 bp, and coded product is made of 398 amino acid, It is signal peptide wherein to have 28 amino acid, remaining 370 Amino acid profile maturation protein, relative molecular weight 43000Da, etc. Electric point pI is 5.1.Alpha toxin is divided into two structural domains, i.e., the C-terminal that the N-terminal structural domain of αhelix and participation memebrane protein combine Structural domain, through experimental results demonstrate there is different activity, N-terminal to have phospholipase C activity, C-terminal tool for N-terminal and the C-terminal of alpha toxin There are sphingomyelinase activity, only the two collaboration that could have hemolytic activity and killing activity.Alpha toxin be C.perfringens most Important virulence factor there is no effective therapy so far.About the research of anti alpha toxin humanized antibody, at home substantially Belong to blank, studies anti-clostridium perfringens alpha toxin therapeutic antibodies and have broad application prospects.
In the 1990s, combinatorial chemistry technique be combined with each other with genetic engineering antibody technology produces Antibody library, Antibody library is exactly to clone repertoire antibody heavy chain and chain variable region gene with gene clone technology, and then recombination is to specifically In prokaryotic expression carrier, then the functional Antibody molecule fragments of Bacillus coli expression are converted, and is obtained specifically by affine screening The technology of property antibody variable gene.Different according to the screening technique used, it is anti-that antibody library experienced Single chain variable fragment, bacteriophage Body library, ribosomal display library three phases, wherein phage antibody library are that so far, development is most ripe, most widely used Antibody technique, phage antibody library refer in filobactivirus surface expression Fab antibody or scFv antibody, this is known as bacteriophage Then antibody recycles genetic engineering means clonal B cell full set variable region gene, is inserted into expression vector, and in bacteriophage Surface expression forms a large amount of phage antibody, phage antibody library is constituted, as created by MRC HGMP resource centers Human Single Fold scFv Libraries I+J (Tomlinson I+J), the library include at least 108It is a Different recombinant single chain antibody gene segments, using its can elutriation go out anti alpha toxin single-chain antibody gene segment.To develop α poison The specific medicament of element poisoning is laid a good foundation, and new foundation is provided.Currently, the preparation of human single chain variable fragments antibody, most of is all profit A phage display library for relying on phage vector or phagemid vector is built with display technique of bacteriophage, passes through mesh Antigen combined with antibody specificity, by a few wheel elutriations and enrichment process, screen required positive colony or purpose Antibody carries out qualitative and quantitative analysis using technologies such as ELISA and PCR to it.
Invention content
The purpose of the present invention is to overcome a variety of side effects of heterogenetic antibody, exempt heterogenetic antibody progress humanization and change The tedious steps made and high cost, and provide that a kind of body molecular weight is small, and internal penetration capacity is strong, the rapid damaged tissues and thin of reaching Born of the same parents play antitoxin effect, clostridium perfringens alpha toxin Humanized single chain antibody 8B.
Clostridium perfringens alpha toxin Humanized single chain antibody 8B, its base sequence is as shown in SEQ ID NO.2.
Clostridium perfringens alpha toxin Humanized single chain antibody 8B, its amino acid sequence is as shown in SEQ ID NO.5.
Clostridium perfringens alpha toxin Humanized single chain antibody 8B is in preparing treatment and prevention clostridium perfringens alpha toxin The application of the drug of poison.
A kind of detection reagent of detection clostridium perfringens alpha toxin, it includes amino acid sequence as shown in SEQ ID NO.5 Clostridium perfringens alpha toxin Humanized single chain antibody 8B.
The present invention provides clostridium perfringens alpha toxin Humanized single chain antibody 8B, it is from phage antibody library Source bioscience are screened, and are the anti-clostridium perfringens alpha toxin antibody in full people source, both may be implemented to neutralize poison The therapeutic effect of element, while a variety of side effects of heterogenetic antibody are overcome, it is humanization modified to eliminate heterogenetic antibody progress Tedious steps and high cost, since single-chain antibody molecules amount is small, internal penetration capacity is strong, rapid to reach damaged tissues and cell Antitoxin effect is played, therefore reaches economic and efficient dual purpose.Alpha toxin has with C.perfringens other types toxin There is certain homology, which is possible to have inhibition and therapeutic effect to other kinds of toxin, also can be used as inspection Test agent detects clostridium perfringens alpha toxin.
Description of the drawings
The double digestion that Fig. 1 is recombinant expression plasmid pET-28a-CPA is identified;M:DL2000 DNA Marker;1:Recombinate table Up to plasmid pET-28a-CPA; 2:After I double digestion of recombinant expression plasmid pET-28a-CPA Nde I and EcoR;
Fig. 2 is expression of results of the engineering bacteria after induction;M:Protein Marker;1:Negative control;2-5:Induce thalline;
Fig. 3 is the expression of results of engineering bacteria in different medium;M:Protein Marker;1:Negative control;2:LB is trained It supports in base and expresses supernatant;3:Precipitation is expressed in LB culture mediums;4:Supernatant is expressed in TB culture mediums;5:It is heavy to be expressed in TB culture mediums It forms sediment;
Fig. 4 is alpha toxin albumen after purification;M:Marker;1:Sample before fibrin ferment digestion;2:Mistake after fibrin ferment digestion Metal chelate chromatography sample;
Fig. 5 is the PCR qualification results of 10 plants of scFv screening positive clone bacterial strains;
Fig. 6 is scFv after purification;M:Marker;1:55% saturation degree ammonium sulfate sample;2:Protein A chromatography flows through 3: Protein A chromatography sample after purification;
Fig. 7 is anti-clostridium perfringens alpha toxin scFv antibody activity qualification results.
Specific implementation mode
Embodiment 1:The structure of recombinant expression plasmid pET-28a-CPA
According to the clostridium perfringens alpha toxin announced in Genbank(CPA)Complete sequence(Genbank accession number L43548.1), the complete genome sequence of clostridium perfringens alpha toxin is designed and synthesized, while Nde is inserted at the difference both ends of gene I and EcoR, I restriction enzyme sites, and be cloned into pMD19-T carriers, plasmid pMD19-T-CPA is built, E.coli is then transferred to In JM109, puncture fungi preservation is made.
By the vector plasmid pET-28a large fragments for purifying recycling after digestion and the CPA digestion products for purifying recycling after digestion It is connected with T4 DNA ligases, obtains recombinant plasmid pET-28a-CPA, convert escherichia coli jm109 competent cell, contain kan The agar plate of resistance carries out preliminary screening.Picking individual colonies are cultivated in LB liquid medium;It is carried with plasmid QIAquick Gel Extraction Kit It takes plasmid, double digestion identification, product to be analyzed through 1% agarose gel electrophoresis, obtains the band of 1125 bp or so, size and insertion Target gene be consistent, and carry out the measurement of sequence, it was demonstrated that CPA target fragments are correctly inserted into carrier, successfully construct recombination Plasmid pET-28a-CPA(See Fig. 1).
Embodiment 2:Expression, purifying and the property of protein research of CPA
By recombinant plasmid pET-28a-CPA conversion expression bacterium-e. coli bl21s(DE3), after IPTG induced expressions, SDS- PAGE results are shown:Recombinant protein c PA has an apparent expression band, size to be consistent with theoretical value at the places 43KD or so, the expression of CPA Amount accounts for the 15.6% of bacterial protein(See Fig. 2).
By recombinant protein expression bacterium lysate supernatant precipitation while SDS-PAGE electrophoresis is done, the results show that destination protein The overwhelming majority is in supernatant, and there is also a small amount of destination proteins for corresponding position in precipitation, by the optimization of inductive condition, suitable It can be expressed with soluble form under induced environment(See Fig. 3).
The purifying of recombinant protein c PA, recombinant protein express thalline through ultrasound crack, successively pass through saturated ammonium sulphate, Metal chelate chromatography after hydrophobic chromatography, metal chelate chromatography, ion-exchange chromatography and fibrin ferment digestion obtains purity 95% Above sterling alpha toxin.Pyrogen quality detection<20EU/mg meets the needs of property of protein research(See Fig. 4).
Embodiment 3:The screening of the anti-clostridium perfringens alpha toxin neutrality scFv antibody of Quan Renyuan
Using the CPA recombinant proteins of purifying as antigen coat in 96 hole elisa Plates, 4 DEG C overnight.Next day abandons supernatant, with 2% 37 DEG C of Milk-PBS closing 2h, the phage antibody library Source bioscience of preparation are added(Britain), it is purchased from Beijing Xi Mei Science and Technology Ltd.s(China's distributors), titre is 1.0 × 1013, acutely shake be incubated 60min at room temperature, stand 60min.After discard liquid, washed 10 times with the PBS containing 0.1%Tween-20, will gently be clapped per residual liquid in hole after washing It is dry, 50 μ L eluents are added per hole(Pancreatin-the PBS of 5mg/mL), 10min is acutely shaken at room temperature, and wash-out bacteriophage collects 4 DEG C preserve.
With the Phage Infection E.coli TG1 of elution, and it is coated on TYE tablets(Portugal containing 100 μ g/mL Amp and 1% Grape sugar)37 DEG C are incubated overnight.Phage library is expanded using helper phage KM13, bacteriophage is recycled by PEG/NaCl.It repeats Above procedure 3 times, totally 4 wheel screening.
Phage Infection after screeningE.ColiHB2151 after induced expression, is identified using ELISA, sets microplate reader measurement OD values(Wavelength is 490nm), each sample does diplopore measurement, takes OD average values.Positive colony bacterial strain determines that standard is:OD values are 3 times or more of negative control.300 plants of positive colony bacterial strains are obtained altogether, are compared by Activity determination, and 10 plants of strong positive clones are obtained Bacterial strain.
According to the gene order of the pIT-2 carriers in Tomlinson I+J kits, synthesis upstream and downstream specific PCR draws Object expands scFv full genome segments.
P1 LMB3: 5’—CAG GAA ACA GCT ATG AC—3’
P2 pHEN: 5’—CTA TGC GGC CCC ATT CA—3’
Determine that target fragment is the genetic engineering antibody segment (Fig. 5) of 900bp or so.
Embodiment 4:Anti- CPA-scFv expression and purifying
Strong positive scFv antibody clonings bacterial strain is cultivated at 37 DEG C, until OD600 to 0.9, is added 30 DEG C of overnight incubations of derivant (16h), for overnight culture in 4 DEG C, 3500 × g centrifuges 30min, and supernatant contains the scFv of expression.Supernatant is induced successively to pass through 55% After saturation degree ammonium sulfate precipitation and rProtein-A affinity chromatographys, sample of the purity 90% or more is obtained(Fig. 6)
Embodiment 5:Anti- CPA-scFv Activity determinations and antibody affinity costant KD values measure
Take 50% Egg Yolk Emulsion(Extra large clear biology, article No. HB8295)4 DEG C of 10000 × g centrifuge 20min, take Supernatant, with physiological saline 1:The diluted yolk liquid of 100 μ L is added per hole in tissue culture plate for 10 times of dilutions, and 5 μ are added per hole The CPA toxin and 5 μ g scFv of g purifying, negative control is done with physiological saline, and only plus CPA toxin does positive control, each sample Product do multiple holes measurement, and 37 DEG C of 2 h of placement read OD620 average values.By comparing light absorption value, it can accurately show that activity is higher Bacterial strain, the lower positive strain activity of light absorption value are better(Fig. 7).8B and 7D plants of acquisition have good neutralization activity, pass through survey Sequence is analysis shows the sequence is typical human single chain variable fragments antibody sequence.
Embodiment 6:The affinity costant of antibody is measured using non-competing enzyme-linked immunization.
The affinity costant that 7D and 8B single-chain antibodies are measured using non-competing enzyme immunoassay, respectively with 2.5 μ g/mL, 1.25 μ G/mL, 0.625 μ g/mL and 0.3125 μ g/mL are coated with alpha toxin, and single-chain antibody concentration is adjusted to 10-6Mol/L, doubling dilution 1:2~1:512, with 1:5000 times of diluted Protein A-HRP antibody measure OD490nm extinctions as secondary antibody, OPD colour developings Value, each sample do diplopore measurement, take OD average values.According to the sigmoid curve figure of antigen-antibody binding reaction, can solve The antibody concentration of half light absorption value under different antigen concentrations, be brought into formula KA=(n-1)It is calculated in/2 (nAb '-Ab) affine normal Number, wherein Ab ' and Ab indicate, when antigen is Ag ' and Ag, to generate the antibody concentration of half light absorption value(mol/L), n=Ag '/Ag, It can obtain 3 KA values as n=2, when n=4 can obtain 2 KA values, and when n=8 obtains 1 KA value, and six KA value mean values is taken to obtain The affinity costant of antibody.
It the results are shown in Table 1:Wherein 7D single-chain antibodies affinity costant is(2.01±0.78)×108L/mol;8B single-chain antibodies Affinity costant is(3.45±0.58)×108L/mol。
The K that 1 anti-CPA single-chain antibodies 7D and 8B affinity determination curve of table acquires after being simulatedAValue
Embodiment 7:In animal body in CPA toxin and Experiment on therapy
It carries out attacking toxic agent quantity research using the CPA toxin of purifying, was to attack malicious all times with 96 hours, it is determined that CPA poison It is 30 μ g/Kg weight that element attacks malicious LD50 to the abdominal cavity of kunming mouse.It is 5 groups to take 30 kunming mouses to be randomly divided into, male and female It is fifty-fifty, if positive and each one group of negative control group, high, medium and low three dosage groups of component are administered, remaining is each in addition to negative control group The CPA toxin of 5 times of LD50 is given in abdominal cavity to group respectively, attack poison after 1 hour positive controls give PBS buffer solution placebo treatment, High dose treatment group gives the scFv of 30 μ g/Kg weight purifying, middle dose group gives the scFv of 20 μ g/Kg weight purifying, low dose Amount group gives the scFv of 10 μ g/Kg weight purifying.Negative control group attacks poison oath and gives PBS buffer solution, and 30 μ are given in treatment experiment The scFv of g/Kg weight purifying.As a result:Positive controls mortality of animals 100%, high dose group are all survived, middle dose group 1 Death, 2 death of low dose group, negative control group are without exception.It can be seen that high dose group mouse protective rate reaches 100%, and In dose-dependence.
By system experiments have shown that the anti-CPA single-chain antibodies that screening obtains have to neutralize a toxin protects energy with experimental animal Power.It is expected that the therapeutic effect to neutralize a toxin may be implemented in human body, while a variety of side effects of heterogenetic antibody are overcome again, It eliminates heterogenetic antibody and carries out humanization modified tedious steps and high cost, then since single-chain antibody molecules amount is small, in vivo Penetration capacity is strong, rapid to reach damaged tissues and the effect of cells play antitoxin, reaches economic and efficient dual purpose.
<110>MILITARY VETERINARY INST ACADE
<120>Clostridium perfringens alpha toxin Humanized single chain antibody 8B
<160> 6
<210> 1
<211> 1125
<212> DNA
<213>Manually
<400> 1
catatgtggg atggaaagat tgatggaaca ggaactcatg ctatgattgt aactcaaggg 60
gtttcaatct tagaaaatga tctgtctaaa aatgaaccag aaagtgtaag aaaaaactta 120
gagattttaa aagagaacat gcatgagctt caattaggtt ctacttatcc agattatgat 180
aagaacgcct atgatctata tcaagatcat ttctgggatc ctgatacaga taataatttc 240
tcaaaggata atagttggta tttagcttat tctatacctg acacagggga atcacaaata 300
agaaaatttt cagcattagc tagatatgaa tggcaaagag gaaactataa acaagctaca 360
ttctatcttg gagaggctat gcactatttt ggagatatag atactccata tcatcctgct 420
aatgttactg ccgttgatag cgcaggacat gttaagtttg agacttttgc agaggaaaga 480
aaagaacagt ataaaataaa cacagcaggt tgcaaaacta atgaggattt ttatgctgat 540
atcttaaaaa acaaagattt taatgcatgg tcaaaagaat atgcaagagg ttttgctaaa 600
acaggaaaat caatatacta tagtcatgct agcatgagtc atagttggga tgattgggat 660
tatgcagcaa aggtaacttt agctaactct caaaaaggaa cagcaggata tatttataga 720
ttcttacacg atgtatcaga gggtaatgat ccatcagttg gaaagaatgt aaaagaacta 780
gtagcttaca tatcaactag tggtgagaaa gatgctggaa cagatgacta catgtatttt 840
ggaatcaaaa caaaggatgg aaaaactcaa gaatgggaaa tggacaaccc aggaaatgat 900
tttatgactg gaagtaaaga cacttatact ttcaaattaa aagatgaaaa tctaaaaatt 960
gatgatatac aaaatatgtg gattagaaaa agaaaatata cagcattccc agatgcttat 1020
aagccagaaa acataaagat aatagcaaat ggaaaagttg tagtggacaa agatataaat 1080
gagtggattt caggaaattc aacttataat ataaaataag aattc 1125
<210> 2
<211> 870
<212> DNA
<213>Manually
<400> 2
ataatgaaat acctattgcc tacggcagcc gctggattgt tattactcgc ggcccagccg 60
gccatggccg aggtgcagctgttggagtct gggggaggct tggtacagcc tggggggtcc 120
ctgagactct cctgtgcagc ctctggattc acctttagca gctatgccat gagctgggtc 180
cgccaggctc cagggaaggg gctggagtgg gtctcaggga ttccgaagca tggtgggcgt 240
acaagttacg cagactccgt gaagggccgg ttcaccatct ccagagacaa ttccaagaac 300
acgctgtatc tgcaaatgaa cagcctgaga gccgaggaca cggccgtata ttactgtgcg 360
aaaggtggga cgatgtttga ctactggggc cagggaaccc tggtcaccgt ctcgagcggt 420
ggaggcggtt caggcggagg tggcagcggc ggtggcgggt cgacggacat ccagatgacc 480
cagtctccat cctccctgtc tgcatctgta ggagacagag tcaccatcac ttgccgggca 560
agtcagagca ttagcagcta tttaaattgg tatcagcaga aaccagggaa agcccctaag 600
ctcctgatct atagggcatc ccgtttgcaa agtggggtcc aatcaaggtt cagtggcagt 660
ggatctggga cagatttcac tctcaccatc agcagtctgc aacctgaaga ttttgcaact 720
tactactgtc aacaggggtc ggcgcgtcct gcgacgttcg gccaagggac caaggtggaa 780
atcaaacggg cggccgcaca tcatcatcac catcacgggg ccgcagaaca aaaactcatc 840
tcagaagagg atctgaatgg ggccgcatag 870
<210> 3
<211> 870
<212> DNA
<213>Manually
<400> 3
ataatgaaat acctattgcc tacggcagcc gctggattgt tattactcgc ggcccagccg 60
gccatggccg aggtgcagct gttggagtct gggggaggct tggtacagcc tggggggtcc 120
ctgagactct cctgtgcagc ctctggattc acctttagca gctatgccat gagctgggtc 180
cgccaggctc cagggaaggg gctggagtgg gtctcacaga tttcgaatca tggtgggtat 240
acagcttacg cagactccgt gaagggccgg ttcaccatct ccagagacaa ttccaagaac 300
acgctgtatc tgcaaatgaa cagcctgaga gccgaggaca cggccgtata ttactgtgcg 360
aaagggtcgc agaggtttga ctactggggc cagggaaccc tggtcaccgt ctcgagcggt 420
ggaggcggtt caggcggagg tggcagcggc ggtggcgggt cgacggacat ccagatgacc 480
cagtctccat cctccctgtc tgcatctgta ggagacagag tcaccatcac ttgccgggca 540
agtcagagca ttagcagcta tttaaattgg tatcagcaga aaccagggaa agcccctaag 600
ctcctgatct atggtgcatc ccgtttgcaa agtggggtcc aatcaaggtt cagtggcagt 660
ggatctggga cagatttcac tctcaccatc agcagtctgc aacctgaaga ttttgcaact 720
tactactgtc aacaggctca gttgattcct gagacgttcg gccaagggac caaggtggaa 780
atcaaacggg cggccgcaca tcatcatcac catcacgggg ccgcagaaca aaaactcatc 840
tcagaagagg atctgaatgg ggccgcatag 870
<210> 4
<211> 372
<212> PRT
<213>Manually
<400> 4
His Met Trp Asp Gly Lys Ile Asp Gly Thr Gly Thr His Ala Met Ile
5 10 15
Val Thr Gln Gly Val Ser Ile Leu Glu Asn Asp Leu Ser Lys Asn Glu
20 25 30
Pro Glu Ser Val Arg Lys Asn Leu Glu Ile Leu Lys Glu Asn Met His
35 40 45
Glu Leu Gln Leu Gly Ser Thr Tyr Pro Asp Tyr Asp Lys Asn Ala Tyr
50 55 60
Asp Leu Tyr Gln Asp His Phe Trp Asp Pro Asp Thr Asp Asn Asn Phe
65 70 75 80
Ser Lys Asp Asn Ser Trp Tyr Leu Ala Tyr Ser Ile Pro Asp Thr Gly
85 90 95
Glu Ser Gln Ile Arg Lys Phe Ser Ala Leu Ala Arg Tyr Glu Trp Gln
100 105 110
Arg Gly Asn Tyr Lys Gln Ala Thr Phe Tyr Leu Gly Glu Ala Met His
115 120 125
Tyr Phe Gly Asp Ile Asp Thr Pro Tyr His Pro Ala Asn Val Thr Ala
130 135 140
Val Asp Ser Ala Gly His Val Lys Phe Glu Thr Phe Ala Glu Glu Arg
145 150 155 160
Lys Glu Gln Tyr Lys Ile Asn Thr Ala Gly Cys Lys Thr Asn Glu Asp
165 170 175
Phe Tyr Ala Asp Ile Leu Lys Asn Lys Asp Phe Asn Ala Trp Ser Lys
180 185 190
Glu Tyr Ala Arg Gly Phe Ala Lys Thr Gly Lys Ser Ile Tyr Tyr Ser
195 200 205
His Ala Ser Met Ser His Ser Trp Asp Asp Trp Asp Tyr Ala Ala Lys
210 215 220
Val Thr Leu Ala Asn Ser Gln Lys Gly Thr Ala Gly Tyr Ile Tyr Arg
225 230 235 240
Phe Leu His Asp Val Ser Glu Gly Asn Asp Pro Ser Val Gly Lys Asn
245 250 255
Val Lys Glu Leu Val Ala Tyr Ile Ser Thr Ser Gly Glu Lys Asp Ala
260 265 270
Gly Thr Asp Asp Tyr Met Tyr Phe Gly Ile Lys Thr Lys Asp Gly Lys
275 280 285
Thr Gln Glu Trp Glu Met Asp Asn Pro Gly Asn Asp Phe Met Thr Gly
290 295 300
Ser Lys Asp Thr Tyr Thr Phe Lys Leu Lys Asp Glu Asn Leu Lys Ile
305 310 315 320
Asp Asp Ile Gln Asn Met Trp Ile Arg Lys Arg Lys Tyr Thr Ala Phe
325 330 335
Pro Asp Ala Tyr Lys Pro Glu Asn Ile Lys Ile Ile Ala Asn Gly Lys
340 345 350
Val Val Val Asp Lys Asp Ile Asn Glu Trp Ile Ser Gly Asn Ser Thr
355 360 365
Tyr Asn Ile Lys
370
<210> 5
<211> 289
<212> PRT
<213>Manually
<400> 5
Iie Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu
5 10 15
Ala Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly
20 25 30
Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
35 40 45
Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro
50 55 60
Gly Trp Gly Leu Glu Trp Val Ser Gly Ile Pro Trp His Gly Gly Arg
65 70 75 80
Thr Ser Tyr Ala Asp Ser Val Trp Gly Arg Phe Thr Ile Ser Arg Asp
85 90 95
Asn Ser Trp Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
100 105 110
Asp Thr Ala Val Tyr Tyr Cys Ala Trp Gly Gly Thr Met Phe Asp Tyr
115 120 125
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
130 135 140
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Thr Asp Ile Gln Met Thr
145 150 155 160
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile
165 170 175
Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln
180 185 190
Gln Trp Pro Gly Trp Ala Pro Trp Leu Leu Ile Tyr Arg Ala Ser Arg
195 200 205
Leu Gln Ser Gly Val Gln Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
210 215 220
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr
225 230 235 240
Tyr Tyr Cys Gln Gln Gly Ser Ala Arg Pro Ala Thr Phe Gly Gln Gly
245 250 255
Thr Trp Val Glu Ile Trp Arg Ala Ala Ala His His His His His His
260 265 270
Gly Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala
275 280 285
Ala
289
<210> 6
<211> 289
<212> PRT
<213>Manually
<400> 6
Iie Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu
5 10 15
Ala Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly
20 25 30
Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
35 40 45
Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro
50 55 60
Gly Lys Gly Leu Glu Trp Val Ser Gln Ile Ser Asn His Gly Gly Tyr
65 70 75 80
Thr Ala Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
85 90 95
Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
100 105 110
Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Ser Gln Arg Phe Asp Tyr
115 120 125
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
130 135 140
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Thr Asp Ile Gln Met Thr
145 150 155 160
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile
165 170 175
Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln
180 185 190
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Gly Ala Ser Arg
195 200 205
Leu Gln Ser Gly Val Gln Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
210 215 220
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr
225 230 235 240
Tyr Tyr Cys Gln Gln Ala Gln Leu Ile Pro Glu Thr Phe Gly Gln Gly
245 250 255
Thr Lys Val Glu Ile Lys Arg Ala Ala Ala His His His His His His
260 265 270
Gly Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala
275 280 285
Ala
289

Claims (4)

1. clostridium perfringens alpha toxin Humanized single chain antibody 8B, its base sequence is as shown in SEQ ID NO.2.
2. clostridium perfringens alpha toxin Humanized single chain antibody 8B, its amino acid sequence is as shown in SEQ ID NO.5.
3. clostridium perfringens alpha toxin Humanized single chain antibody 8B is preparing treatment and prevention clostridium perfringens alpha toxin poisoning Drug in application.
4. a kind of detection reagent of detection clostridium perfringens alpha toxin, it includes amino acid sequence as shown in SEQ ID NO.5 Clostridium perfringens alpha toxin Humanized single chain antibody 8B.
CN201410771046.3A 2014-12-15 2014-12-15 Clostridium perfringens alpha toxin Humanized single chain antibody 8B Active CN104531730B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410771046.3A CN104531730B (en) 2014-12-15 2014-12-15 Clostridium perfringens alpha toxin Humanized single chain antibody 8B

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410771046.3A CN104531730B (en) 2014-12-15 2014-12-15 Clostridium perfringens alpha toxin Humanized single chain antibody 8B

Publications (2)

Publication Number Publication Date
CN104531730A CN104531730A (en) 2015-04-22
CN104531730B true CN104531730B (en) 2018-07-17

Family

ID=52847355

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410771046.3A Active CN104531730B (en) 2014-12-15 2014-12-15 Clostridium perfringens alpha toxin Humanized single chain antibody 8B

Country Status (1)

Country Link
CN (1) CN104531730B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105420212B (en) * 2015-12-15 2020-02-14 中国农业科学院哈尔滨兽医研究所 Novel mycobacterium tuberculosis extracellular nuclease and application thereof
CN114891098B (en) * 2022-03-28 2023-08-18 深圳康体生命科技有限公司 Clostridium perfringens beta toxin nano antibody and application thereof
CN117051003B (en) * 2023-10-11 2024-01-26 内蒙古大学 Clostridium perfringens fusion antibody and its preparation method and use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198352A (en) * 2005-04-18 2008-06-11 谢尔英·普劳有限公司 C. perfringens alpha toxoid vaccine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2185631T3 (en) * 1992-05-20 2003-05-01 Secr Defence CLOSTRIDIUM PERFRINGENS VACCINES.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198352A (en) * 2005-04-18 2008-06-11 谢尔英·普劳有限公司 C. perfringens alpha toxoid vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
产气荚膜梭菌α毒素的原核表达及纯化;于佳 等;《中国生物制品学杂志》;20141031;第27卷(第10期);摘要,第1.4节 *

Also Published As

Publication number Publication date
CN104531730A (en) 2015-04-22

Similar Documents

Publication Publication Date Title
CN107189997A (en) The streptococcus bacteriophage lysin for detecting and treating for gram-positive bacteria
CA3103656A1 (en) Antibodies against disease causing agents of poultry and uses thereof
CN104844712B (en) Streptococcus pneumoniae protein antigen and its preparation method and application
Cao et al. Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth
De Amicis et al. Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes
CN104877019B (en) Acinetobacter bauamnnii assumes the albumen and preparation method and application of albumin A 1S_1523
CN104531730B (en) Clostridium perfringens alpha toxin Humanized single chain antibody 8B
Li et al. Mimotopes selected with a neutralizing antibody against urease B from Helicobacter pylori induce enzyme inhibitory antibodies in mice upon vaccination
CN104861049B (en) Acinetobacter bauamnnii 1A1S_1969 recombinant proteins and its preparation method and application
CN102816246B (en) Human cytomegalo virus immunogen fusion protein as well as preparation method and usage thereof
CN106008710B (en) The single-chain antibody and preparation method thereof of the anti-enterotoxigenic escherichia coli K88 FaeG albumen of one boar source property
CN103724413B (en) Trichina paramyosin B cell antigen epi-position 8A1 and application thereof
CN104861050B (en) Acinetobacter bauamnnii zinc relies on Gly-Lys-Ala-Phe-Val-Lys-Lys 1S_1610 albumen and its preparation method and application
CN104531731B (en) Clostridium perfringens alpha toxin Humanized single chain antibody 7D
CN104059134A (en) Recombinant pasteurella multocida toxin protein and application thereof
CN105198992B (en) A kind of preparation method of anti-Vibrio vulnificus haemolysis fibroin (VVH) antibody in people source and application
CN106478777B (en) Staphylococcus aureus FnBPA A albumen mimic epitope peptide, mimic epitope peptide combinations and its application with immune protective
CN101781632A (en) Brucella melilitensis bp26 gene-deleted M5-90 vaccine strain
CN104861048B (en) Acinetobacter bauamnnii assumes albumin A 1S_1462 albumen and preparation method and application
CN104774263B (en) The human single chain variable fragments antibody 4C-scFv of anti-botulinum toxin type B enzymatic activity and its application
CN113754782A (en) Helicobacter pylori egg yolk antibody and preparation method and application thereof
Li et al. Identification and characterization of antigenic epitope of Staphylococcus aureus ClfA adhesin
CN103319593B (en) Anti StxII monoclonal antibody
Oghalaie et al. Development and characterization of nanobody against envenomation by Naja naja oxiana
CN101357942B (en) Monoclonal antibody, Fab antibody and application for neutralizing enterohemorrhagic escherichia coli o157:H7 shiga toxin II

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant